{"generic":"Indium In 111 Oxyquinoline","drugs":["Indium In 111 Oxyquinoline"],"mono":{"0":{"id":"925126-s-0","title":"Generic Names","mono":"Indium In 111 Oxyquinoline"},"1":{"id":"925126-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925126-s-1-4","title":"Adult Dosing","mono":"<b>Finding of lesion; Diagnosis - Inflammatory disorder; Diagnosis:<\/b> (70 kg patient) 7.4 to 18.5 megabecquerels (MBq) (200 to 500 microcuries) IV "},"1":{"id":"925126-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"925126-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Finding of lesion; Diagnosis - Inflammatory disorder; Diagnosis<br\/>"}}},"3":{"id":"925126-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925126-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"925126-s-3-10","title":"Precautions","mono":"<ul><li>blood borne pathogen transmission potential; implement procedures to avoid administration errors and viral contamination of personnel<\/li><li>cell aggregates, various degrees, have been reported; contributing factors include labeling technique and standing of cell preparation<\/li><li>children less than 18 years of age; potential for delayed onset of long-term adverse effects and high radiation burden<\/li><li>elderly; dosage adjustment may be necessary<\/li><li>false-negative scans; due to loss of chemotaxis during cell storage; increased risk with storage of radiolabeled cells beyond 1 hour (3 hours at most)<\/li><li>focal accumulations of radioactivity in the lungs; cell clumping in lungs increases potential for false-positive results; image chest immediately after injection<\/li><li>heart pool activity; hemolyzed blood in radiolabeled leukocytes should be avoided<\/li><li>leukopenia; use not recommended due to low number of available leukocytes<\/li><li>radiopharmaceutical, maintain adequate shielding and handle with care to minimize exposure to the patient and personnel<\/li><li>reinjection of radiolabeled cells beyond 5 hours from initial blood drawing not recommended<\/li><li>spleen and liver; high uptake of radiolabeled leukocytes in these organs may mask inflammatory lesions<\/li><\/ul>"},{"id":"925126-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"925126-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"5":{"id":"925126-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction<br\/>"},"6":{"id":"925126-s-6","title":"Drug Name Info","sub":{"2":{"id":"925126-s-6-19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"925126-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925126-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"925126-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Labeling of leukocytes: When incubated with leukocytes, which have been isolated from whole blood, the indium-oxyquinoline complex, being lipid-soluble, penetrates the cell membrane of the leukocytes. Within the cell the radioactive indium dissociates from oxyquinoline and becomes firmly attached to cytoplasmic components, while the nonradioactive oxyquinoline is released by the cell.<\/li><li>Diagnosis of inflammatory lesions: The radioactive autologous leukocytes are subsequently reinjected to permit the detection of inflammatory lesions based on the normal physiological accumulation of leukocytes at such sites.      <\/li><li>Labeling of platelets, diagnosis of thrombosis: The radiolabeled autologous platelets, when reinjected, deposit at sites of vascular endothelium injury as a normal hemostatic response. This permits detection of thrombi. <\/li><\/ul>"},"8":{"id":"925126-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"925126-s-8-26","title":"Excretion","mono":"Systemic: Renal and Fecal: &lt;1%          <br\/>"},"4":{"id":"925126-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Systemic: Biological: Clearance of indium In 111-labeled leukocytes from whole blood: 5 to 10 hours; Clearance of indium In 111-labeled platelets from whole blood: 7 to 10 days. <\/li><li>Systemic: 7 to 10 d<\/li><\/ul>"}}},"9":{"id":"925126-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>use proper procedures for handling and disposal of radiopharmaceuticals<\/li><li>use aseptic procedures and maintain appropriate shielding throughout the labeling and administration procedures<\/li><li>wear waterproof gloves during the handling and administration procedure<\/li><li>withdraw 30 to 50 mL of blood from patient using a syringe containing approximately 1000 to 1500 units heparin in 1 to 2 mL; cap and label the syringe, gently mix the contents<\/li><li>allow the RBCs to sediment 30 to 60 minutes until the leukocyte rich plasma looks clear of RBCs; after replacing the syringe cap with an infusion set, express the plasma through catheter tubing into a centrifuge tube labeled &quot;WBC&quot;, ensuring no RBCs get into the WBC tube<\/li><li>immediately centrifuge the WBC tube at 400 to 450 g for 5 minutes and transfer the supernatant to a centrifuge tube labeled &quot;LPP&quot;, leaving 0.5 to 1 mL supernatant behind to cover the white cell button; wash the white cell button with 4 to 6 mL sodium chloride (0.9%) and resuspend the button with gentle swirling<\/li><li>centrifuge the WBC tube at 400 to 450 g for 5 minutes and discard all but 0.5 to 1 mL of supernatant to cover the cells; add 5 mL sodium chloride (0.9%) and resuspend the cells with gentle swirling<\/li><li>add 22.2 megabecquerels (600 microcuries) indium in 111 oxyquinoline to the WBC tube, gently swirling after each addition; allow the WBC tube to incubate for 15 minutes, swirling the preparation several times during incubation.<\/li><li>using a sterile plastic syringe, add half of the LPP tube contents to the WBC tube; gently swirl the WBC tube contents to resuspend the cells and centrifuge the WBC tube at 450 g for 5 minutes or 150 g for 8 minutes and discard all but 0.5 mL of supernatant to cover the cells.<\/li><li>assay the activity in the WBC tube and in the discarded washings with a dose calibrator and record; using a sterile plastic syringe, add the LPP tube contents to the cell button and resuspend by gentle swirling; with a sterile syringe, draw the cells up and express the suspension against the tube gently once or twice<\/li><li>draw up the patient's dose (7.4 to 18.5 megabecquerels (200 to 500 microcuries)) from the WBC tube and just prior to administration, measure dose with a suitable radioactivity calibration system and check the leukocyte preparation for gross clumping and RBC contamination<\/li><li>indium in 111 oxyquinoline-labeled autologous leukocytes should be injected within 1 hour of preparation<\/li><\/ul>"},"10":{"id":"925126-s-10","title":"Monitoring","mono":"image quality of radiolabeled leukocytes is indicative of efficacy<br\/>"},"11":{"id":"925126-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Injection Solution: 1 MCI\/ML<br\/>"},"13":{"id":"925126-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause sensitivity reactions, such as urticaria.<\/li><li>Instruct patient to notify their healthcare provider if they are breastfeeding or intend to breastfeed during or around the time of therapy; formula feedings are recommended.<\/li><\/ul>"}}}